These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 22226627

  • 1. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S.
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [Abstract] [Full Text] [Related]

  • 2. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I, van der Hoek K, Melosky B, Peacock S.
    J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB, NCIC Clinical Trials Group Working Group on Economic Analysis.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):298-306. PubMed ID: 20160168
    [Abstract] [Full Text] [Related]

  • 5. Erlotinib for the treatment of relapsed non-small cell lung cancer.
    McLeod C, Bagust A, Boland A, Hockenhull J, Dundar Y, Proudlove C, Davis H, Green J, Macbeth F, Stevenson J, Walley T, Dickson R.
    Health Technol Assess; 2009 Jun 03; 13 Suppl 1():41-7. PubMed ID: 19567213
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
    Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, de la Orden M.
    J Int Med Res; 2010 Jun 03; 38(1):9-21. PubMed ID: 20233509
    [Abstract] [Full Text] [Related]

  • 7. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ, Wong WB, Veenstra DL, Reyes C.
    J Med Econ; 2011 Jun 03; 14(2):159-66. PubMed ID: 21288059
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA, Rudakova AV.
    Vopr Onkol; 2015 Jun 03; 61(4):676-80. PubMed ID: 26571844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL.
    Value Health; 2009 Jun 03; 12(1):20-7. PubMed ID: 18647257
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C.
    Respirology; 2009 Jul 03; 14(5):709-15. PubMed ID: 19659649
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B, Chen H, Shen J, Ye M.
    Clin Ther; 2011 Oct 03; 33(10):1446-55. PubMed ID: 21992806
    [Abstract] [Full Text] [Related]

  • 19. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
    Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.
    Lung Cancer; 2009 May 03; 64(2):199-206. PubMed ID: 18951651
    [Abstract] [Full Text] [Related]

  • 20. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
    Doral Stefani S, Giorgio Saggia M, Vicino dos Santos EA.
    J Med Econ; 2008 May 03; 11(3):383-96. PubMed ID: 19450094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.